Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 193 of the 194 references it cites were found in a registry or an index.

Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis

Open access

Abstract

BACKGROUND: The evidence on selective serotonin reuptake inhibitors (SSRIs) for major depressive disorder is unclear. METHODS: Our objective was to conduct a systematic review assessing the effects of SSRIs versus placebo, 'active' placebo, or no intervention in adult participants with major depressive disorder. We searched for eligible randomised clinical trials in The Cochrane Library's CENTRAL, PubMed, EMBASE, PsycLIT, PsycINFO, Science Citation Index Expanded, clinical trial registers of Europe and USA, websites of pharmaceutical companies, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency until January 2016. All data were extracted by at least two independent investigators. We used Cochrane systematic review methodology, Trial Sequential Analysis, and calculation of Bayes factor. An eight-step procedure was followed to assess if thresholds for statistical and clinical significance were crossed. Primary outcomes were reduction of depressive symptoms, remission, and adverse events. Secondary outcomes were suicides, suicide attempts, suicide ideation, and quality of life. RESULTS: ). The effect estimate, however, was below our predefined threshold for clinical significance of 3 HDRS points. SSRIs significantly decreased the risk of no remission (RR 0.88; 95% CI 0.84 to 0.91; P < 0.00001; 34 trials; Trial Sequential Analysis adjusted CI 0.83 to 0.92); Bayes factor (1426.81) did not confirm the effect). SSRIs significantly increased the risks of serious adverse events (OR 1.37; 95% CI 1.08 to 1.75; P = 0.009; 44 trials; Trial Sequential Analysis-adjusted CI 1.03 to 1.89). This corresponds to 31/1000 SSRI participants will experience a serious adverse event compared with 22/1000 control participants. SSRIs also significantly increased the number of non-serious adverse events. There were almost no data on suicidal behaviour, quality of life, and long-term effects. CONCLUSIONS: SSRIs might have statistically significant effects on depressive symptoms, but all trials were at high risk of bias and the clinical significance seems questionable. SSRIs significantly increase the risk of both serious and non-serious adverse events. The potential small beneficial effects seem to be outweighed by harmful effects. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42013004420.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-016-1173-2

Cites

193 of 193 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA flowchart
Fig. 1 PRISMA flowchartCC BY · PubMed Central
Fig. 2 Random-effects meta-analysis of the results on the Hamilton depression rating scale
Fig. 2 Random-effects meta-analysis of the results on the Hamilton depression rating scaleCC BY · PubMed Central
Fig. 3 Risk of bias in the included randomized clinical trials
Fig. 3 Risk of bias in the included randomized clinical trialsCC BY · PubMed Central
Fig. 4 Subgroup analysis comparing trials assessing the effects of different selective serotonin reuptake inhibitors
Fig. 4 Subgroup analysis comparing trials assessing the effects of different selective serotonin reuptake inhibitorsCC BY · PubMed Central
Fig. 5 Subgroup analysis comparing trials randomising elderly participants to trials randomising non-elderly participants
Fig. 5 Subgroup analysis comparing trials randomising elderly participants to trials randomising non-elderly participantsCC BY · PubMed Central
Fig. 6 Subgroup analysis comparing trials using a placebo-washout period to trials not using a placebo-washout period
Fig. 6 Subgroup analysis comparing trials using a placebo-washout period to trials not using a placebo-washout periodCC BY · PubMed Central
Fig. 7 Trial Sequential Analysis of the results of selective serotonin reuptake inhibitors on Hamilton depression rating scale
Fig. 7 Trial Sequential Analysis of the results of selective serotonin reuptake inhibitors on Hamilton depression rating scaleCC BY · PubMed Central
Fig. 8 Funnel plot of the random-effects meta-analysis of the effect of selective serotonin reuptake inhibitors on Hamilton depression rating scale
Fig. 8 Funnel plot of the random-effects meta-analysis of the effect of selective serotonin reuptake inhibitors on Hamilton depression rating scaleCC BY · PubMed Central
Fig. 9 Random-effects meta-analysis of the results of selective serotonin reuptake inhibitors on remission of depression
Fig. 9 Random-effects meta-analysis of the results of selective serotonin reuptake inhibitors on remission of depressionCC BY · PubMed Central
Fig. 10 Trial Sequential Analysis of the results of selective serotonin reuptake inhibitors on remission of depression
Fig. 10 Trial Sequential Analysis of the results of selective serotonin reuptake inhibitors on remission of depressionCC BY · PubMed Central
Fig. 11 Random-effects meta-analysis of the results of selective serotonin reuptake inhibitors on serious adverse events
Fig. 11 Random-effects meta-analysis of the results of selective serotonin reuptake inhibitors on serious adverse eventsCC BY · PubMed Central
Fig. 12 Trial Sequential Analysis of the results of selective serotonin reuptake inhibitors on serious adverse events
Fig. 12 Trial Sequential Analysis of the results of selective serotonin reuptake inhibitors on serious adverse eventsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

14 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 194 references

Research works printed but not linked: 9

  1. Beck A, Steer RA, Brown GK. Beck depression inventory—second edition: manual. San Antonio: Psychological Corporation. 1996;4:561–71.
  2. The Nordic Cochrane Centre (The Cochrane Collaboration): Review Manager (RevMan) [Computer program]. Version 5.3. In.; 2008.
  3. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA). Copenhagen: Copenhagen Trial Unit, Centre for Clinical Intervention Research; 2011. p. 1–115. Available from http://www.ctu.dk/tsa .
  4. Fabre LF, Crismon L. Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res Clin Exp. 1985;37(1):1985.
  5. Rickels K, Amsterdam JD, Avallone MF. Fluoxetine in major depression: A controlled study. Curr Ther Res Clin Exp. 1986;39(4):1986.
  6. MY-1045/BRL-029060/1 (PAR128) (Unpublished Data) GlaxoSmithKline. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder. http://www.gsk-clinicalstudyregister.com/files2/2821.pdf 2005, 1:1–5.
  7. MY-1043/BRL-029060/115 (Unpublished Data) GlaxoSmithKline. A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder. http://www.gsk-clinicalstudyregister.com/files2/2060.pdf 2005, 175:1–5.
  8. SCT-MD-26 (Unpublished Data) Forest Research Institute. Two-week double-blind placebo controlled study of escitalopram in the treatment of severe major depression. 2005, 135:2–4.
  9. SCT-MD-27 (Unpublished Data) Forest Research Institute. A double-blind flexible dose comparison of escitalopram sertraline and placebo in the treatment of major depressive disorder. 2005, 91:5–7.

Cited by

See all 366

Metadata

Authors
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., Krogh, J., Ebert, S. E., Timm, A., Lindschou, J., & Gluud, C.
Affiliations
  • Copenhagen University Hospital (DK)
  • University of Copenhagen (DK)
Corresponding author
Jakobsen, Janus Christian
Venue
BMC Psychiatry
Published
2017-02-08
Volume
17
Issue
1
Pages
162-162
ISSN
1471-244X (ISSN-L)
OpenAlex
W2586384568
Cited by
366
References
194
Citations by year
2026: 30 · 2025: 38 · 2024: 30 · 2023: 38 · 2022: 32 · 2021: 42 · 2020: 35 · 2019: 52 · 2018: 43 · 2017: 26
FWCI
5.42
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
Funders
  • Rigshospitalet
  • Copenhagen Trial Unit, Centre for Clinical Intervention Research
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
selective serotonin reuptake inhibitors, major depressive disorder, antidepressant efficacy, placebo comparison, remission, adverse drug reactions, suicide risk, quality of life, trial bias, antidepressant safety, trial sequential analysis, Bayes factor, quality of evidence, antidepressant-induced mania, antidepressant-induced hypomania
MeSH terms
Adult, Depressive Disorder, Humans, Placebos, Quality of Life, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. https://app.cochat.ai/papers/10.1186/s12888-016-1173-2
The paper
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., Krogh, J., Ebert, S. E., Timm, A., Lindschou, J., & Gluud, C. (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. https://doi.org/10.1186/s12888-016-1173-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.